Here's how an activist investor is threatening a Peninsula drug maker's merger plans. And the drama introduces a potential ...

Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding ...

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

Concentra Biosciences LLC, controlled by San Diego's Tang Capital Partners LP, made an unsolicited offer at $3 per share plus ...

The interest from Concentra Biosciences includes an offer to purchase all outstanding shares of ACELYRIN at $3.00 each, plus a contingent value right tied to 80% of net proceeds from potential future ...

Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in ...

Portman Ridge Finance Corporation (NASDAQ: PTMN ) Click to Take Action Portman Ridge Finance Corporation has agreed to be acquired by Logan Ridge Finance Corporation. Under the proposed agreement, ...

Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash payment of $3.00 per share, along with a ...

Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...